SpliceBio

SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. Their lead program, SB-007, aims to treat Stargardt disease by producing a functional copy of the full-length ABCA4 protein. The company’s platform leverages engineered proteins (inteins) to overcome the limitations of AAV vectors in delivering large genes.

Funding Round: Series B

Funding Amount: $135M

Date: 11-Jun-2025

Investors: EQT Life Sciences, Sanofi Ventures, Roche Venture Fund, New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, Asabys Partners

Markets: Biotech, Gene Therapy, Ophthalmology, Neurology

HQ: Barcelona, Spain

Founded: 2012

Website: http://www.splice.bio/

LinkedIn: https://www.linkedin.com/company/splicebio/

Twitter: https://twitter.com/SpliceBioHQ

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/proteodesign

Pitchbook: https://pitchbook.com/profiles/company/100654-03